Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Rectal Cancer Patients × Bevacizumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 382 Carcinoma, Non-Small-Cell Lung 196 Breast Neoplasms 166 Ovarian Neoplasms 148 Glioblastoma 134 Neoplasms 110 Carcinoma, Hepatocellular 101 Rectal Neoplasms 97 Colonic Neoplasms 95 Neoplasm Metastasis 91 Brain Neoplasms 85 Lung Neoplasms 74 Fallopian Tube Neoplasms 69 Glioma 62 Carcinoma, Renal Cell 61 Pancreatic Neoplasms 45 Melanoma 39 Gliosarcoma 39 Adenocarcinoma of Lung 36 Liver Neoplasms 35 Stomach Neoplasms 34 Uterine Cervical Neoplasms 33 Recurrence 33 Astrocytoma 28 Triple Negative Breast Neoplasms 24 Endometrial Neoplasms 24 Carcinoma, Ovarian Epithelial 23 Esophageal Neoplasms 21 Kidney Neoplasms 19 Colorectal Cancer Metastatic 18

Interventions

Radiotherapy 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01426074 2018-08-21

DCE-MRI PET Bevacizumab Study in Rectal Cancer

Abramson Cancer Center at Penn Medicine

Phase 2 Withdrawn

Gastrointestinal

Rectal Cancer Patients

Data powered by HemOnc (CC BY 4.0) Colophon ⚡